ReviewJournal of endocrinological investigation2002
Mitochondrial diabetes mellitus.
Review in Journal of endocrinological investigation, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 26 citations in OpenAlex.
- Calorie restriction increases muscle mitochondrial biogenesis in healthy humans.PLoS medicine · 2007Trial
- The correlation between the rs2241767 variant and the plasma AdipoQ concentration in type 2 diabetes mellitus: A case - control study.Medicine · 2026Article
- Nonlinear relationship between serum ferritin and diabetic retinopathy in patients with type 2 diabetes mellitus: mediating role of neutrophil-to-albumin ratio.Frontiers in endocrinology · 2026Article
- Monogenic diabetes: the role of mitochondrial dysfunction and endoplasmic reticulum stress.Frontiers in clinical diabetes and healthcare · 2025Review
- Restoring energy metabolism by NADFood science & nutrition · 2024Article
- Iron and the Pathophysiology of Diabetes.Annual review of physiology · 2023Review
- Spotlight on iron and ferroptosis: research progress in diabetic retinopathy.Frontiers in endocrinology · 2023Review
- Endocrinological and metabolic characteristics in patients who are non-obese and have polycystic ovary syndrome and different types of a family history of type 2 diabetes mellitus.The Journal of international medical research · 2021Article
- Deciphering the Nutraceutical Potential ofNutrients · 2019Review
- Adiponectin: Probe of the molecular paradigm associating diabetes and obesity.World journal of diabetes · 2015Review
- Advancing animal models of human type 1 diabetes by engraftment of functional human tissues in immunodeficient mice.Cold Spring Harbor perspectives in medicine · 2012Review
- Article
- Insulin, IGF-1 and longevity.Aging and disease · 2010Article
- Role of adiponectin in human skeletal muscle bioenergetics.Cell metabolism · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This review discusses the current insight by which mutations in mitochondrial DNA (mtDNA) contribute to the development of particular disease states with emphasis on diabetes mellitus. Mitochondria are the power factories of the cells and produce ATP by oxidizing reducing equivalents via the respiratory chain. These reducing equivalents originate mainly from the citric acid cycle that also occurs within the mitochondria. Human mitochondria contain their own genetic material in the form of circular DNA that encodes for only a fraction of the mitochondrial components. The other mitochondrial components are nuclear encoded. Pathogenic mutations in mtDNA can affect the activity of the respiratory chain, thereby leading to the reduced generation of ATP. However, mitochondria not only produce ATP but they also regulate cytosolic concentrations of signaling molecules such as calcium and iron ions. The metabolic processes within mitochondria such as the citric acid cycle determine the concentration of metabolites that can also act as signalling molecules. Furthermore, the respiratory chain and mitochondrion-associated monoamine oxidase are major producers of reactive oxygen radicals. As a result, mutations in mtDNA can deregulate multiple processes within cells and the balance of this deregulation may contribute to the clinical phenotype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.